Navigation Links
Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
Date:10/7/2008

U.S. National Institutes of Health, The Infectious Disease Research Institute and Eli Lilly and Company Announce Launch and Board of Advisors

SEATTLE, Oct. 7 /PRNewswire-FirstCall/ -- The Lilly TB Drug Discovery Initiative today announced its first acquisition of compounds for further development into tuberculosis (TB) drug candidates. Agreements were reached with Summit plc (LSE: SUMM) of Oxfordshire, UK, and the Microbial Chemistry Research Foundation (MCRF) of Tokyo for two compounds that have shown potential in initial testing.

The announcement marked the commencement of the Initiative's work and the opening of new laboratories focused on early drug discovery for TB. It also coincided with the first meeting of the non-profit organization's Board of Advisors and Scientific Steering Committee.

The Lilly TB Drug Discovery Initiative is a public-private partnership with the goal of filling the early-stage pipeline for future drug development. Created in June 2007, the Initiative's primary members are Eli Lilly and Company, the Infectious Disease Research Institute (IDRI), and the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).

"I've seen first-hand the toll that TB takes on families in all corners of the world. People think of TB as a disease of the past, but with extensive spread of resistance to current drugs and without rapid development of new drugs, TB will be a disease of the future everywhere, including here in the U.S.," said Dr. Paul Farmer of Partners In Health and Harvard Medical School, who sits on the Initiative's Board of Advisors.

The access this public-private Initiative has to proprietary chemical libraries of compounds is unique. The Initiative will accelerate identification of new clinical candidates by bringing together specialists from around the world for the systematic exploration of vast, private molecular libraries. It will bring t
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. UPDATE: Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
2. RG Global Corporate Update: First Coal Bed Methane Water Treatment Plant Near Completion; Expanding Water Treatment Applications
3. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
4. Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA
5. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
6. Lilly Declares Fourth-Quarter Dividend
7. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
10. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
11. Lilly Announces Termination of AIR Insulin Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Medical Systems (NYSE: VAR ), world leader in ... to sustainability with inclusion on a prestigious list of the ... equipment company among the Corporate Knights Global 100 Most Sustainable ... Davos, Switzerland . "We ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The report ... by Product Type & Provider Type - Global Advancements, ... market with an in-depth analysis and forecasting of revenues. ... spread through 221 pages and in-depth TOC on “Service ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases filed ... are in the process of being consolidated in a Kansas ... Re: Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 ... , Management of the Syngenta GMO corn multidistrict litigation (MDL) ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... 17 Digital Union announced today they,have entered ... (Southeast,Regional Genetics Group) in Region 3 to provide ... states, Puerto Rico and the,US Virgin Islands. The ... has received additional funding for another five-year period.,With ...
... Technologies and ... Decade, ST. LOUIS, Aug. 17 Monsanto Company ... Biosafety,Technical Committee (CTNBio) approved the company,s MON 810 insect,protection ... Borer,for future commercial use in corn in Brazil. ...
... The Foundation,for Taxpayer and Consumer Rights (FTCR) today praised ... Interstate Alliance for Stem Cell,Research to the public saying ... science. The decision came after a closed,session of the ... Warren Wollschlager, of the Connecticut Department of Health and ...
Cached Biology Technology:Digital Union's RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative 2Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait 2Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision 2
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... German . Waiting: a clever move! , ... prominent ,Stanford Marshmallow Experiment,: the children were presented with a marshmallow ... and receive a second one if the first one was still ... were able to wait for the delayed reward showed greater success ...
... Conn. , March 13, 2013 /PRNewswire-iReach/ -- ... and biologics will need to address the current ... innovative ideas for developing antibodies against intracellular and ... for infectious disease and CNS applications. The versatility ...
... household pesticide contamination emphasizes the need for less ... blocking cracks where insects can enter and other ... concluded. Their study appears in the ACS, journal ... Lu and colleagues cite previous studies showing that ...
Cached Biology News:Doing business with a parrot 2Engineering Stream Conferences at PEGS 2013 2Engineering Stream Conferences at PEGS 2013 3
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
SHP-2 Antibody...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
... an early protein. Can ... post-infection exhibiting an intranuclear inclusion ... between 6-24 hours. These ... granular staining. No other ...
Biology Products: